SEOUL-SEMICONDUCTOR
7.12.2021 11:02:11 CET | Business Wire | Press release
From a research study 30% of dentists will suffer from visual reduction capabilities in the next 30 years. For FARO, the solutions are already here.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211207005033/en/
With the new dentist lamp Eva and the new ceiling panel Siderea equipped with SunLike LED technology, the historical and global market leader in the orthodontist equipment sector FARO wants to keep demonstrating their technological leadership and implement the latest technology available that can improve the healthcare of the users.
FARO has developed 2 new products with edge technology that will improve patients and doctors' lives, as new products include solar spectrum light that will help on concentration, relax and recovery activities as demonstrated by recent studies done by University of Basel and Harvard medical school.
The Eva lamp, completely developed, tested and manufactured in FARO headquarters in Ornago, near Milan, represents a technological revolution in the market. After many years of research the reflector is perfectly adapted to the new LED technology obtaining the perfect system combination that brings the best possible light and beam angle to the needed place.
The version Eva Sunlight uses the special SunLike LEDs from Seoul Semiconductor with a solar spectrum at any colour temperature of the light and produces the closest light to the real and natural Sunlight.
With an illumination of 50.000 lux the Eva luminaire can guide the professionals to see all the smallest details in their day to day operations and guarantee at the same time the maximum visual comfort for the patient and the dentist.
Talking about technical parameters the new luminaire is achieving the greatest quality of the light with a CRI of 97 and a TM30 of 100 that brings a perfect vision and colour reproduction of the oral cavities.
To get immediate feedback on the lighting level in use, you just have to take a look at the headlamp; it is also possible to manage all the functions from smartphones and tablets using the app FARO Tech that is available in all app stores.
Finally, Eva has an integrated camera (Eva Cam) which allows you to photograph and video record footage in FHD or even 4K to broadcast live or share images later on.
Siderea Sunlight is the natural complement of the Eva lamp. With the Theia Tech – the special lamp that talks with the intensive light – reducing the stress of the pre-operation for patients.
This combination of Siderea and Eva forms the FARO light system that has been developed to guarantee the ideal conditions for developing the dentists' work.
Siderea is the only dentist panel in the market with technology SunLike that mimics the effects of the natural light with a uniform, multidirectional and proportional light and it deletes all the shadows from traditional lamps. Reassuring the wellbeing and visual effects to operate in the perfect ambient.
“To improve people lives: this is our inspiration as entrepreneurs” explains Cristina Cesari, General Manager of FARO that today counts more than 700 customers, with products installed in more than 70 countries around the world.
“To reproduce the natural light is our main research driver and is a challenge of great fascination. Today we can bring the benefits of Seoul Semiconductor SunLike technology into the health medical area and improve all professional environments” added Cristina Cesari.
Oliver Schaefer, Executive Vice-president for Seoul Semiconductor Europe said “We are very honoured and proud to be part of the new FARO products with our latest LED technology SunLike that brings the Sun benefits to indoor spaces”.
About FARO
FARO is an historic Italian brand for lighting in the dental sector. FARO stands for high Italian quality, creativity and innovation. We provide products and “lighting systems” to improve the “light experience” because light is not only seen, but above all life and well-being. We are an enthusiastic company serving demanding and visionary customers. In FARO we provide cutting-edge technologies that are considered industry benchmarks, we work enthusiastically to go beyond the boundaries of research to enable the next generation of professional lighting.
About Seoul Semiconductor
Seoul Semiconductor develops and commercializes LEDs for automotive, general illumination, specialty lighting, and backlighting markets. As the second-largest LED manufacturer globally excluding the captive market, Seoul Semiconductor holds more than 14,000 patents, offers a wide range of technologies, and mass produces innovative LED products such as SunLike, WICOP, NanoDriver and nPola as examples.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211207005033/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom